MedTrace Logo

Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies

NCT04068597 · Status: RECRUITING · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 250

Last updated 2025-12-18

No results posted yet for this study

Summary

A Phase 1/2a study to assess the safety, tolerability, PK and biological activity of CCS1477 (inobrodib) in patients with Non-Hodgkin Lymphoma, Multiple Myeloma, Acute Myeloid Leukaemia or High Risk Myelodysplastic syndrome.

Conditions

Interventions

DRUG

CCS1477

Oral capsule

DRUG

Pomalidomide

oral capsule

DRUG

Dexamethasone

oral tablet

DRUG

Azacitidine

Powder suspension for Injection

DRUG

Venetoclax

Oral tablet

DRUG

Bortezomib

Powder for solution for injection

DRUG

Ixazomib

Oral capsule

DRUG

Elranatamab

Solution for injection

DRUG

Teclistamab

Solution for injection

DRUG

Lenalidomide

Oral capsule

DRUG

Daratumumab

Solution for injection, concentrate for solution for infusion

Sponsors & Collaborators

  • CellCentric Ltd.

    lead INDUSTRY

Principal Investigators

  • Tim Somervaille · The Christie NHS Foundation Trust

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-08-09
Primary Completion
2027-03-31
Completion
2027-03-31
FDA Drug
Yes

Countries

  • United States
  • France
  • Spain
  • Sweden
  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04068597 on ClinicalTrials.gov